TOP HEADLINES

Featured Story

  • Protein discovery could help kill stubborn latent HIV

    Researchers at the Salk Institute for Biological Studies have uncovered a protein that plays a role in active HIV replication, essentially acting as part of a switch to turn HIV-1, the most common type of HIV, from a dormant state to an active one.

Gut bacterium in mosquitoes could combat malaria, dengue

A bacterium found in the gut of an Aedes mosquito may have therapeutic applications for malaria and dengue, two diseases transmitted by these mosquitoes.

Brain cells reprogrammed from skin cells offer treatment hope for Huntington's

Using a new cell programming method, researchers at Washington University in St. Louis have converted human skin cells directly into a type of brain cell that is damaged by Huntington's disease.

Toxin-producing stem cells designed to kill brain tumors

Scientists have figured out a way to harness stem cells so that they can be used to produce and emit toxins capable of killing brain tumors.

Government halts research on dangerous airborne pathogens

The White House is temporarily shutting down biomedical research of dangerous pathogens, such as MERS, SARS and pandemic flu strains following several embarrassing safety incidents at government labs.

Case Western, Janssen, Oncodesign scientists ID anti-inflammatory compounds

Investigators have pegged two compounds that appear to reduce inflammation associated with a wide range of diseases such as ulcerative colitis, arthritis and multiple sclerosis.

MORE NEWS

From Our Sister Sites

FierceBiotech

A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.

FierceBiotech

In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.